Skip to main content

Table 1 SMNa Risk

From: Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children’s Oncology Group

Treatment Arm Dexrazoxane Doxorubicin Ifosfamide Etoposide
AOST0121 HER2+ 3.75 g/m2 375 mg/m2 51 g/m2 1.5 g/m2
AOST0121 HER2- 3.75 g/m2 375 mg/m2 51 g/m2 1.5 g/m2
P9754 Pilot 1 Good Response 4.5 g/m2 450 mg/m2   
P9754 Pilot 1 Standard Response 6 g/m2 600 mg/m2   
P9754 Pilot 2 Good Response 4.5 g/m2 450 mg/m2 27 g/m2  
P9754 Pilot 2 Standard Response 6 g/m2 600 mg/m2 45 g/m2  
P9754 Pilot 3 Good Response 4.5 g/m2 450 mg/m2 27 g/m2  
P9754 Pilot 3 Standard Response 4.5 g/m2 450 mg/m2 60 g/m2 1.5 g/m2
  1. aSMN second malignant neoplasms